Blood Biomarkers for Alzheimer Disease and Neuro-injury to Estimate the Association With Cognitive/Functional Decline and Mortality in a Real-world Population of GERiatric Hospitalized Patients (BAD-GER): a Multicenter, Observational, 3-arms, Prospective Study
NCT: NCT07435467 ·
Status: RECRUITING ·
Phase: N/A
· Sponsor: Istituto Nazionale di Ricovero e Cura per Anziani
· Started: 2025-04-09
· Est. Completion: 2026-06-30
Official Summary
The BAD-GER study is a multicenter, prospective, three-arm observational study serving to validate a prognostic biomarker algorithm for mortality and hospital readmission; this algorithm will be developed through the retrospective analysis of Alzheimer's Disease and neurodegeneration biomarkers in an already available discovery cohort of 700 previously hospitalized geriatric patients.
Study Design
- Study Type: OBSERVATIONAL
- Enrollment: 400 participants
Interventions
- OTHER: collection of blood samples — Serum and EDTA-plasma samples will be collected at baseline
Primary Outcomes
- All-cause Mortality (12 months from enrollment)
- Number of hospital readmission (12 months from enrollment)
Secondary Outcomes
- Comprehensive geriatric assessment by INTERRAI-MDS-AC/VAOR-AC instrument (At baseline)
- Levels of amyloid ß-42 (At baseline)
- Assessment of cognitive function (At baseline)
- Assessment of cognition (At baseline)
- Assessment of frailty (At baseline)
Trial Locations
- IRCCS INRCA Hospital, Ancona, Italy
- IRCCS INRCA Hospital, Fermo, Italy
- Policlinico Universitario, Messina, Italy
More Alzheimer Disease Trials
AI-generated analysis for educational purposes only. This is not medical advice. Discuss clinical trial participation with your doctor. Data sourced from ClinicalTrials.gov.